Creative Planning
STLN

Creative Planning’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Creative Planning’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.5K Sell
26,212
-52,421
-67% -$161K ﹤0.01% 3936
2025
Q4 		$280K Buy
+78,633
New +$292K ﹤0.01% 3292

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Creative Planning's STLN Position: Q1 2026 in Review

Creative Planning reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 67% in Q1 2026, selling an estimated $161K and leaving 26,212 shares worth $80.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3936.

Creative Planning first reported a position in STLN in Q4 2025 and has held it in 2 quarters since. The position peaked at $280K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Creative Planning held 26,212 shares of Starling Oncology Institute, Inc. Common Stock worth $80.5K as of Q1 2026.
  • Creative Planning sold 52,421 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $161K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3936 holding.
  • Creative Planning first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 2 quarters since.
  • Creative Planning's Starling Oncology Institute, Inc. Common Stock position peaked at $280K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.